Journal of Medicinal Chemistry · 2013 · 30 citations · 49 references
MedicineCardiologyPharmacologyCalcium HomeostasisDrug DiscoveryMolecular PharmacologyAntiarrhythmic TherapyCalcium SignalingCardiac Ion ChannelsCardiac PharmacotherapyHeart Failure PharmacotherapyIntracellular Calcium SignalingAntiarrhythmic PharmacologyCalcium Channel PharmacodynamicsCalcium Channel PharmacologyCalcium Handling In CardiomyocytesCalcium-induced Calcium ReleaseCardiac Calcium HandlingIntracellular Calcium ReleaseRyanodine Receptors
Carvedilol is a uniquely effective drug for the treatment of cardiac arrhythmias in patients with heart failure. This activity is in part because of its ability to inhibit store-overload-induced calcium release (SOICR) through the RyR2 channel. We describe the synthesis, characterization, and bioassay of ca. 100 compounds based on the carvedilol motif to identify features that correlate with and optimize SOICR inhibition. A single-cell bioassay was employed on the basis of the RyR2-R4496C mutant HEK-293 cell line in which calcium release from the endoplasmic reticulum through the defective channel was measured. IC50 values for SOICR inhibition were thus obtained. The compounds investigated contained modifications to the three principal subunits of carvedilol, including the carbazole and catechol moieties, as well as the linker chain containing the β-amino alcohol functionality. The SAR results indicate that significant alterations are tolerated in each of the three subunits.
49
Philip A. Poole‐Wilson, Karl Swedberg, John G.F. Cleland et al. · The Lancet · 2003 · 1.9K citations · Full text
Medicine, Cardiology, Pharmacology +13
Protection from Cardiac Arrhythmia Through Ryanodine Receptor-Stabilizing Protein Calstabin2
Xander H.T. Wehrens, Stephan E. Lehnart, Steven Reiken et al. · Science · 2004 · 477 citations
Medicine, Cardiology, Pharmacology +17